NanoViricides Inc. (NNVC): if that is your answer then, like I said...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Re: malibuman post# 78125

Sunday, 01/05/2014 3:48:55 PM

Sunday, January 05, 2014 3:48:55 PM

if that is your answer then, like I said, you are not very well versed on exchange transitions as they relate to development of short interest.

Keep Last Read

Replies (1) Next 10 Prev Next

Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2024 09:30:36 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/15/2024 08:44:44 PM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/27/2024 08:15:38 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM

InvestorsHub NewsWire

Only $200 per official company press release!